Lamivudine-Stavudine (Generic)

This Combination of drugs is commonly used in the management of HIV infection. Both Lamivudine and Stavudine belong to the neucleoside analogue class of antiretroviral drugs.

Each Uncoated Tablet Contains(Lamivudine 150mg+Stavudine 30mg) :

Satvudine 30mg
Lamivudine 150mg

Each Uncoated Tablet Contains (Lamivudine 150mg+Stavudine 40mg) :


Satvudine 40mg
Lamivudine 150mg


Each Combination Tablet contains half of the commonly prescribed daily doses of both stavudine and lamivudine. With the availibility of this combination tablet patients maybe better able to adhere to complex drug treatmen regimens, thereby enhancing complaince.

Recommended Dose:

Adults : For patients weighing <60 Kgs Take Lamivudine 150mg + Stavudine 30mg, 1 Tablet, Twice daily.

Adults : For patients weighing >=60 Kgs Take Lamivudine 150mg + Stavudine 40mg, 1 Tablet, Twice daily.

Please consult your health care professional before taking this combination and take exactly as prescribed. As this is a fixed dose combination, this medication should not be prescribed for patients requiring dosage adjustment, such as those with reduced renal function, those with low body weight(<50 Kgs or 110lb), or those experiencing dose limiting adverse events.

Lactic Acidosis and severe Hepatomegaly with steatosis, including fatal cases, have been reported with the use of neucleoside analogues alone or in combination including lamivudine and stavudine.
Consult your health care professional for more information.

This medication is contraindicated in patients with clinically significant hypersensitivity to any of the components contained in the formulation.

Lamivudine : There is no known antidote for Lamivudine. It is not known whether lamivudine can be removed by peritoneal dyalisis or haemodialysis.

Stavudine : Stavudine can be removed by haemodialysis. Experience with adults treated with 12 to 24 times the recommended daily dosage revealed no acute toxicity. Complications of chronic overosage include peripheral neuropathy and hepatic toxicity.

When stavudine is used in combination with other agents with similar toxicities, the incidence of adverse events may be higher than when stavudine is used alone. Pancreatitis, Peripheral neuropathy, and liver function abnormalities occur more frequently in patients treated with the combination of stavudine.

Do not double dose to make up for the missed dose. Consult your doctor for dosages and take exactly as directed.

Both drugs act by inhibiting the reverse transcriptase of HIV, and by terminating the growth of the DNA chain. Stavudine in combination with lamivudine has been shown to have synergistic antiretroviral activity.

The medication is not intended for use in Pediatric Patients

Store in a cool dry place.

Stavudine therapy has rarely been associated with motor weakness, occuring predominantly in the setting of lactic acidosis. If motor weakness develops or the patient is suspected with lactic acidosis, immediately suspend therapy with stavudine. Permanent discontinuation should be considered for patients with confirmed lactic acidosis.

Stavudine therapy has also been associated with peripheral sensory neuropathy, which can be severe, is dose related, and occurs more frequently in patients being treated with neurotoxic drug therapy, including didanosine, in patients with advanced HIV infection, or in patients who have previously experienced peripheral neuropathy.

Patients should be monitored for the development of neuropathy. Stavudine related neuropathy may resolve is therapy is withdrawn promptly, in some cases symptoms may worsen temporarily following the discontinuation of therapy. If symptoms resolve completely, patients may tolerate resumption of treatment at one half of the dose, If neuropathy recurs thereafter, discontinuation of stavudine should be considered.